Professor Peter McHugh, Interim President of University of Galway, has been elected Fellow of the European Mechanics Society (EUROMECH). Professor McHugh is the first person from the Republic of Ireland to receive the prestigious Fellowship award. Professor McHugh was awarded the EUROMECH Solid Mechanics Fellowship for his outstanding scientific contributions to biomechanics, biomedical engineering and mechanical engineering and the development of biomedical engineering research and education programmes. By honouring him in such a way, the EUROMECH Council recognises eminent scientific contributions to the advancement of Solid Mechanics. The prestigious accolade is awarded to just three Fellows every three years, and there currently are only 20 EUROMECH Solid Mechanics Fellows. The European Mechanics Society will officially confer Fellowship on Professor McHugh at the 12th European Solid Mechanics Conference, which takes place in Lyon, France in July.             Professor McHugh said: “I am delighted to become a Fellow of the European Mechanics Society. It is an enormous honour to have my contribution to research and scholarship, and its application in technological development and education, recognised in this way. I look forward to supporting the work of the Council and to continue to work with colleagues from across Europe and beyond to identify and promote new research directions.” Originally from Ballyhaunis, Co Mayo, Professor McHugh is an internationally recognised research leader in biomedical engineering and his research is focused on fundamental developments and applications of computational and experimental methods in biomechanics, tissue mechanics and medical implants and devices. He has been a pioneer in the development of biomedical engineering research and education in Ireland and internationally. Professor McHugh joined the University in 1991 and was appointed as the first Established Professor of Biomedical Engineering in 2007. He has served as Dean of College of Engineering and Informatics, Head of School of Engineering, and as Deputy President and Registrar of the University, and was appointed as Interim President of University of Galway in September 2024. The European Mechanics Society is an international scientific organisation whose objective is to engage in all activities to promote the development of mechanics as a branch of science and engineering, ranging from fundamental research on the behaviour of solids and fluids to applied research in engineering. The status of Fellow of EUROMECH is awarded to members of the Mechanics community who have contributed significantly to the advancement of mechanics and related fields. This may be through their original research and publications, or their innovative contributions in the application of mechanics and technological developments, or though their distinguished contribution to the discipline in other ways. Ends

University of Galway has announced the appointment of Dr Finn Krewer as the inaugural holder of the Greally Lectureship in Applied Clinical Data Analytics. The creation of the lectureship and Dr Krewer’s appointment is landmark initiative in integrating advanced clinical data analysis with cutting-edge research in artificial intelligence and healthcare. The Greally Lectureship, endowed on behalf of University graduates Professor John F. and Dr Marie Greally, represents a collaboration between the University’s College of Medicine, Nursing and Health Sciences and the Insight Research Ireland Centre for Data Analytics and confirms ambition to advance clinical research through data-driven innovation. Professor Peter McHugh, Interim President of University of Galway, said: “The creation of the Greally Lectureship and Dr Finn Krewer’s appointment is a significant step in advancing University of Galway’s leadership in Applied Clinical Data Analytics. With the support of Professor John F. and Dr Marie Greally, this lectureship underscores our ambition to harness data-driven innovation to tackle complex healthcare challenges. Dr Krewer’s expertise will play a vital role in realising our vision of transforming clinical research and healthcare delivery through cutting-edge analytics and artificial intelligence.” Dr Marie Greally said: “We are delighted that Dr Krewer will be the first recipient of the lectureship, which we are privileged to have been able to endow as a symbol of the value and excitement of incorporating research into medical practice. We wish him every success and hope it acts as an inspiration to the next generation of students.”   Professor John F Greally said: “Dr Krewer has an extraordinary record of accomplishment already in his career. We look forward to his continued success, applying his skills to clinical data with the goal of improving health care.” Dr Krewer is a graduate of University of Galway and completed his PhD in Engineering in 2017 on bio-inspired reconfigurable computing. His research seamlessly combined biological neuron models with hardware accelerators, earning him numerous university and national scholarships. Since then, Dr Krewer has built a distinguished career, publishing several research papers and gaining industry experience in software development and data analysis. In 2023, Dr Krewer joined University of Galway as a Research Fellow, focusing on applied machine learning techniques for biosignal classification. His current work, supported by a Health Research Board Secondary Data Analysis Project grant, investigates traditional and novel risk factors for stroke in individuals with kidney failure in Ireland. As part of his new role under the Greally Lectureship, Dr Krewer will lead advanced teaching in data analytics and pursue a programme of research addressing clinical data analytics and the applications of artificial intelligence in healthcare.             Professor Martin O’Donnell, Executive Dean of the College of Medicine, Nursing and Health Sciences at University of Galway, said: "Dr Krewer brings exceptional expertise in clinical data analytics and artificial intelligence, which will play a pivotal role in shaping the future of healthcare research. His work will be instrumental in advancing our plans to extend a multi-platform MSc in Applied Clinical Data Analytics, fostering innovations in clinical data analytics and developing our Academic Health Analytic infrastructure. These initiatives aim to bridge traditional and emerging data analysis methods, fostering new insights into mechanisms of disease and advancing population health. We are extremely grateful to Professor John F. and Dr Marie Greally for their generosity.” Ends

Aquila Bioscience developing pathogen decontamination technology for safer space exploration University of Galway spin-out Aquila Bioscience is collaborating with the European Space Agency (ESA) to develop a nature-inspired pathogen decontamination technology for safer space exploration. Traditional antimicrobial measures, while effective on Earth, present significant limitations in space due to potential toxicity, pathogen resistance, and long-term stability concerns. The unique conditions of spaceflight elevate the risk of infectious diseases by altering both human and microbial physiology. Aquila Bioscience’s approach to pathogen decontamination is informed by an extensive review of International Space Station microbiome research, which identified key pathogens posing health risks in confined space environments. These include viruses, bacteria and fungi that cause respiratory, gastrointestinal, urinary and skin infections. Professor Lokesh Joshi, Founder of Aquila Bioscience and Stokes Professor of Glycosciences at University of Galway, said: “Aquila Bioscience is committed to addressing the critical challenges of pathogen exposure in space. Our Pathogen Capturing Technology aligns with the principles of safety, sustainability and innovation that are essential for the future of space exploration. We are honoured to have the European Space Agency’s support as we push the boundaries of innovation. This collaboration underscores the importance of developing sustainable, non-toxic and effective solutions for challenges associated with space exploration.” Aquila Bioscience is pioneering a groundbreaking solution to enhance health and safety protocols for space missions called Pathogen Capturing Technology (PCT). Unlike traditional antimicrobials that may lead to pathogen mutations, sterilisation tolerance, or antimicrobial resistance (AMR), Aquila Biosciences technology provides a safe, effective and eco-friendly alternative that is stable over long periods as space agencies and commercial spaceflight companies strive to ensure the health and safety of their crews. Professor Joshi said: “The deployment of our pathogen control technology in space missions has the potential to revolutionise decontamination protocols, enhancing the safety and well-being of astronauts while supporting sustainable and responsible space exploration.” Aquila Bioscience’s innovative technology employs a selection of natural protein-carbohydrate molecules on a biodegradable matric that act as molecular-Velcro, to capture and remove harmful pathogens without damaging human skin or surfaces. The Pathogen Capturing Technology’s biodegradable composition also addresses critical spaceflight constraints such as payload weight and waste management, ensuring its suitability for long-duration missions. The solution has been inspired by the knowledge of how nature protects humans from germs encountered on a regular basis, offering a non-toxic alternative to conventional decontamination agents like alcohol, bleach, and ammonium compounds, which are often unsuitable for skin use due to their harshness and potential toxicity. The project is sponsored by the European Space Agency (ESA) under ESA Initial Support for Innovation (EISI) activities, funded through the Discovery Programme. Ends